193 related articles for article (PubMed ID: 30561761)
1. A decision analysis comparing 3 active surveillance protocols for the treatment of patients with low-risk prostate cancer.
White C; Nimeh T; Gazelle GS; Weinstein MC; Loughlin KR
Cancer; 2019 Mar; 125(6):952-962. PubMed ID: 30561761
[TBL] [Abstract][Full Text] [Related]
2. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM
Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
[TBL] [Abstract][Full Text] [Related]
4. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.
Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Stewart ST; Bhatnagar V; Sweeney CJ; Stahl JE; McMahon PM
JAMA; 2010 Dec; 304(21):2373-80. PubMed ID: 21119084
[TBL] [Abstract][Full Text] [Related]
5. Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness.
Kang SK; Mali RD; Prabhu V; Ferket BS; Loeb S
Radiology; 2021 Sep; 300(3):594-604. PubMed ID: 34254851
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment.
Zubek VB; Konski A
Mol Diagn Ther; 2009; 13(1):31-47. PubMed ID: 19351214
[TBL] [Abstract][Full Text] [Related]
7. The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer.
Koerber F; Waidelich R; Stollenwerk B; Rogowski W
BMC Health Serv Res; 2014 Apr; 14():163. PubMed ID: 24721557
[TBL] [Abstract][Full Text] [Related]
8. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Active Surveillance, Radical Prostatectomy and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial.
Sharma V; Wymer KM; Borah BJ; Barocas DA; Thompson RH; Karnes RJ; Boorjian SA
J Urol; 2019 Nov; 202(5):964-972. PubMed ID: 31112105
[TBL] [Abstract][Full Text] [Related]
10. Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis.
Reddy D; van Son M; Peters M; Bertoncelli Tanaka M; Dudderidge T; Cullen E; Ho CLT; Hindley RG; Emara A; McCracken S; Orczyk C; Shergill I; Mangar S; Nigam R; Virdi J; Moore CM; Arya M; Shah TT; Winkler M; Emberton M; Falconer A; Belsey J; Ahmed HU
J Med Econ; 2023; 26(1):1099-1107. PubMed ID: 37656223
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer.
Magnani CJ; Hernandez-Boussard T; Baker LC; Goldhaber-Fiebert JD; Brooks JD
J Urol; 2022 Jul; 208(1):80-89. PubMed ID: 35212570
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy for low risk localised prostate cancer.
Lao C; Edlin R; Rouse P; Brown C; Holmes M; Gilling P; Lawrenson R
BMC Cancer; 2017 Aug; 17(1):529. PubMed ID: 28789623
[TBL] [Abstract][Full Text] [Related]
13. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer.
Roth JA; Ramsey SD; Carlson JJ
Oncologist; 2015 Dec; 20(12):1355-64. PubMed ID: 26482553
[TBL] [Abstract][Full Text] [Related]
15. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.
Cooperberg MR; Ramakrishna NR; Duff SB; Hughes KE; Sadownik S; Smith JA; Tewari AK
BJU Int; 2013 Mar; 111(3):437-50. PubMed ID: 23279038
[TBL] [Abstract][Full Text] [Related]
16. The economics of active surveillance for prostate cancer.
Dall'Era MA
Curr Opin Urol; 2013 May; 23(3):278-82. PubMed ID: 23449496
[TBL] [Abstract][Full Text] [Related]
17. [Economic features of active surveillance].
Huguet J; Musquera M; Ribal MJ; Alcaraz A
Arch Esp Urol; 2014 Jun; 67(5):509-13. PubMed ID: 24914850
[TBL] [Abstract][Full Text] [Related]
18. Economic analysis of active surveillance for localized prostate cancer.
Kim S; Dall'Era MA; Evans CP
Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of focal high-intensity focussed ultrasound vs active surveillance for low- to intermediate-risk prostate cancer using a Markov multi-state model.
Bénard A; Duroux T; Robert G
BJU Int; 2019 Dec; 124(6):962-971. PubMed ID: 31298775
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review.
Becerra V; Ávila M; Jimenez J; Cortes-Sanabria L; Pardo Y; Garin O; Pont A; Alonso J; Cots F; Ferrer M;
BMC Health Serv Res; 2016 Oct; 16(1):541. PubMed ID: 27716267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]